Central Venous Catheter Market 2019 | Industry Dynamics By Top Players AngioDynamics, Inc., C. R. Bard, Inc., Teleflex Incorporated, B. Braun Melsungen AG, Medtronic Plc., Vygon Ltd., Cook Medical, Inc., Argon Medical Devices, Inc., ICU Medical, Inc.

Central venous catheters consist of a long, thin tube that is inserted into a large vein to deliver medication, nutrition, intravenous fluids, and cancer medications. Different types of central venous catheters can be utilized by patients according to the duration of the treatment, which includes tunneled central venous catheters (CVC) and implanted ports for long term use, peripherally inserted central catheter (PICC) for intermediate term and nontunneled CVC for short term use.

The global central venous catheter market size was valued at US$ 1,167.4 million in 2017, and is expected to exhibit a CAGR of 6.2% over the forecast period (2018 – 2026).

Free Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/2400

Market Dynamics

Increasing prevalence of renal diseases is a major factor driving central venous catheter market growth. According to the research survey done by U.S. Renal Data System (USRDS), in 2017, around 440,000 patients are living with End-Stage Renal Disease (ESRD) in the U.S and require hemodialysis for survival annually. Moreover, introduction of innovative products and increasing requirement of long-duration IV therapies such as chemotherapy is expected to boost the market growth. For instance, in May, 2018, Pursuit Vascular, Inc., received U.S. Food and Drug Administration (FDA) clearance for a broader indication of its ClearGuard HD caps to include reduction in the incidence of central-line associated bloodstream infection (CLABSI) in hemodialysis patients with central venous catheters (CVCs).

Central venous catheterization is used for chemotherapy administration, total parenteral nutrition, administration of intravenous fluids, administration of blood and platelet transfusions, and other uses. High prevalence of cancer is expected to propel demand for central venous catheterization, which in turn is expected to drive the market growth. According to the World Health Organization (WHO), 2012, cancer is the second leading cause of morbidity and mortality worldwide, with around 14 million new cases registered in 2012 and in 2015, cancer was responsible for 8.8 million deaths worldwide. Moreover, WHO stated that the number of new cases is expected to rise by around 70% by 2030.

Similarly, according to the study by University of California, 2014, around 2 million people worldwide are affected by end stage renal disease (ESRD) and the number of patients diagnosed with the disease is expected to increase at a rate of 5-7% annually.

North America holds dominant position in the global central venous catheter market, owing to high availability of catheters in medical settings. According to the survey by PavMed, 2016, around 7 million central vascular access devices are utilized annually in the U.S., which includes 400-500,000 implantable ports. Increasing prevalence of cancer in the region is also expected to boost the market growth. According to the American Cancer Society, 2017, cancer is the second most common cause of death in the U.S., which accounts for nearly 1 out of every 4 deaths.

Moreover, increase in central venous infections is expected to enhance demand for novel antimicrobial catheters, thereby reducing economic burden caused due to hospitalization. For instance, according to the Cincinnati Children’s Hospital Medical Center, 2014, around 250,000 central venous catheter infections occur annually, procuring the total cost of US$ 7.5- 11 Bn annually to the U.S. healthcare system. Moreover, key players in the players are focused on receiving U.S. Food and Drug Administration (FDA) approval for novel products to reduce the burden of blood stream infections associated with central venous catheters. For instance, in May, 2018, Pursuit Vascular, Inc., received U.S. FDA clearance for a broader indication of its ClearGuard HD caps to include reduction in the incidence of central-line associated bloodstream infection (CLABSI) in hemodialysis patients with central venous catheters (CVCs).

Get Free PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/2400

Key Players

Major players operating in the global central venous catheter market include, AngioDynamics, Inc., C. R. Bard, Inc., Teleflex Incorporated, B. Braun Melsungen AG, Medtronic Plc., Vygon Ltd., Cook Medical, Inc., Argon Medical Devices, Inc., ICU Medical, Inc., and Theragenics Corporation.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.